论文部分内容阅读
目的研究血清C的反应蛋白(CRP),并且测定其在肺癌患者治疗过程中的使用价值。方法在112例已经确诊的患有肺癌的患者中提取血清,之后通过血清的CRP水平来进行检测,然后分析CRP水平与肺癌中的分型以及肺癌分期之间的关系,并且将患者在治疗前的CRP水平与治疗后的CRP水平相比较。结果将各种类型的肺癌与正常人进行比较,其中的差异对统计学来说都有着重要的作用。(p<0.01),而且肺癌的各个类型的CRP水平检测的差异对于统计学来说没有作用(p>0.05),而且III期肺癌患者的CRP的检测水平与II期肺癌患者相比,其中差异(p<0.01,t=8.34)对于统计学来说有着重要的意义。但是IV期肺癌患者的CRP的水平与II期肺癌患者(p<0.01,t=9.84)以及III期肺癌患者(p<0.01,t=11.26)相比较,其中的差异在统计学方面仍然有着重要的意义。在患者经过治疗以后,患者的CRP水平与治疗之前相比有着明显的降低,其中的差异对统计学来说有着重要的作用(p<0.05)。结论肺癌早起患者的诊断可以将CRP的水平作为标记物,并且可以将CRP的水平作为疗效的评价以及癌症分期的检测指标。
Objective To study the serum C-reactive protein (CRP) and determine its value in the treatment of lung cancer patients. Methods Serum samples were obtained from 112 patients with lung cancer who had been diagnosed and then tested by serum CRP levels. Then the relationship between CRP levels and lung cancer classification and lung cancer staging was analyzed, and patients were treated before treatment. The level of CRP was compared with the level of CRP after treatment. As a result, various types of lung cancer were compared with normal people, and the differences among them played an important role in statistics. (p<0.01), and the differences in CRP levels detected in various types of lung cancer were not statistically significant (p>0.05), and the level of CRP detected in stage III lung cancer patients was significantly different from that in stage II lung cancer patients. (p<0.01, t=8.34) is of statistical significance. However, the level of CRP in patients with stage IV lung cancer was significantly lower than that of stage II lung cancer patients (p<0.01, t=9.84) and stage III lung cancer patients (p<0.01, t=11.26). The significance. After the patient was treated, the patient’s CRP level was significantly lower than before the treatment, and the difference was statistically significant (p<0.05). Conclusion The diagnosis of early-onset lung cancer patients can use CRP as a marker, and the level of CRP can be used as an evaluation of efficacy and detection indicators of cancer staging.